KBC Group
EVFM

KBC Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

KBC Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-358
Closed -$16K – 1302
2020
Q2 		$16K Buy
+358
New +$24.1K ﹤0.01% 1263

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KBC Group's EVFM Position: Q3 2020 in Review

KBC Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2020, closing a stake of 358 shares — an estimated $16K sold.

KBC Group first reported a position in EVFM in Q2 2020 and held it in 1 quarter. The position peaked at $16K in Q2 2020. 99 funds tracked by Wall St. Rank hold EVFM as of Q3 2020.

  • KBC Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • KBC Group sold 358 Evofem Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $16K.
  • KBC Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • KBC Group's Evofem Biosciences, Inc. Common Stock position peaked at $16K in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2020.

Based on KBC Group's 13F filing for Q3 2020, filed 28 Oct 2020.